JP2022529642A5 - - Google Patents
Info
- Publication number
- JP2022529642A5 JP2022529642A5 JP2021561601A JP2021561601A JP2022529642A5 JP 2022529642 A5 JP2022529642 A5 JP 2022529642A5 JP 2021561601 A JP2021561601 A JP 2021561601A JP 2021561601 A JP2021561601 A JP 2021561601A JP 2022529642 A5 JP2022529642 A5 JP 2022529642A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- pharmaceutically acceptable
- acceptable salt
- solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962834671P | 2019-04-16 | 2019-04-16 | |
| US62/834,671 | 2019-04-16 | ||
| PCT/US2020/028363 WO2020214734A1 (en) | 2019-04-16 | 2020-04-15 | Bicyclic compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022529642A JP2022529642A (ja) | 2022-06-23 |
| JP2022529642A5 true JP2022529642A5 (enExample) | 2023-04-19 |
| JP7653362B2 JP7653362B2 (ja) | 2025-03-28 |
Family
ID=72838396
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021561601A Active JP7653362B2 (ja) | 2019-04-16 | 2020-04-15 | 二環式化合物 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11420935B2 (enExample) |
| EP (1) | EP3956033B1 (enExample) |
| JP (1) | JP7653362B2 (enExample) |
| KR (1) | KR102909464B1 (enExample) |
| CN (1) | CN114072207B (enExample) |
| AU (1) | AU2020257207A1 (enExample) |
| BR (1) | BR112021020629A2 (enExample) |
| CA (1) | CA3137025A1 (enExample) |
| DK (1) | DK3956033T3 (enExample) |
| ES (1) | ES3014444T3 (enExample) |
| FI (1) | FI3956033T3 (enExample) |
| HU (1) | HUE070525T2 (enExample) |
| IL (1) | IL287222B2 (enExample) |
| MX (1) | MX2021012638A (enExample) |
| PL (1) | PL3956033T3 (enExample) |
| SG (1) | SG11202111404XA (enExample) |
| TW (1) | TWI849107B (enExample) |
| WO (1) | WO2020214734A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210108367A (ko) | 2018-11-09 | 2021-09-02 | 비바체 테라퓨틱스, 인크. | 비시클릭 화합물 |
| MX2021012638A (es) | 2019-04-16 | 2022-01-04 | Vivace Therapeutics Inc | Compuestos biciclicos. |
| WO2021102204A1 (en) * | 2019-11-20 | 2021-05-27 | Vivace Therapeutics, Inc. | Heteroaryl compounds |
| US11787775B2 (en) | 2020-07-24 | 2023-10-17 | Genentech, Inc. | Therapeutic compounds and methods of use |
| WO2022120355A1 (en) | 2020-12-02 | 2022-06-09 | Ikena Oncology, Inc. | Tead degraders and uses thereof |
| CA3205726A1 (en) | 2021-01-25 | 2022-07-28 | Alfredo C. Castro | Combination of a 3-(imidazol-4-yl)-4-(amino)-benzenesulfonamide tead inhibitor with an egfr inhibitor and/or mek inhibitor for use in the treatment of lung cancer |
| AU2022212825A1 (en) * | 2021-01-26 | 2023-08-24 | The United States Government As Represented By The Department Of Veterans Affairs | Compositions and methods for inhibiting yap |
| WO2022221866A1 (en) | 2021-04-16 | 2022-10-20 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
| CA3177022A1 (en) * | 2021-05-11 | 2022-11-11 | Opna Immuno-Oncology Sa | Compounds and methods for yap/tead modulation and indications therefor |
| JP2024519845A (ja) * | 2021-05-19 | 2024-05-21 | ジェネンテック， インコーポレイテッド | 併用療法 |
| TW202317104A (zh) * | 2021-06-25 | 2023-05-01 | 美商賽迪拉治療股份有限公司 | Ｔｅａｄ抑制劑及其用途 |
| WO2023057371A1 (en) | 2021-10-04 | 2023-04-13 | Basilea Pharmaceutica International Ag, Allschwil | 1,2,4-oxadiazol-5-one derivatives for the treatment of cancer |
| WO2023060227A1 (en) | 2021-10-07 | 2023-04-13 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
| CA3248820A1 (en) * | 2022-01-28 | 2023-08-03 | Opna Bio SA | COMPOUNDS AND METHODS FOR YAP/TEAD MODULATION AND RELATED INDICATIONS |
| WO2023173053A1 (en) | 2022-03-10 | 2023-09-14 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
| WO2023173057A1 (en) | 2022-03-10 | 2023-09-14 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
| KR20250029773A (ko) * | 2022-03-22 | 2025-03-05 | 스포로스 바이오디스커버리, 인크. | Tead 억제제 및 사용 방법 |
| US11878958B2 (en) | 2022-05-25 | 2024-01-23 | Ikena Oncology, Inc. | MEK inhibitors and uses thereof |
| EP4554931A1 (en) * | 2022-07-12 | 2025-05-21 | Adama Makhteshim Ltd. | Process for preparing substituted benzamides |
| CN119968359A (zh) | 2022-09-29 | 2025-05-09 | 英矽智能科技知识产权有限公司 | Tead抑制剂及其使用方法 |
| WO2024092116A1 (en) | 2022-10-26 | 2024-05-02 | Ikena Oncology, Inc. | Combination of tead inhibitors and egfr inhibitors and uses thereof |
| IL320456A (en) | 2022-10-27 | 2025-06-01 | Suzhou Genhouse Bio Co Ltd | Phosphorus-containing compound, pharmaceutical composition and use thereof |
| US20240197715A1 (en) | 2022-11-18 | 2024-06-20 | Novartis Ag | Pharmaceutical combinations and uses thereof |
| WO2024173761A1 (en) | 2023-02-17 | 2024-08-22 | Ikena Oncology, Inc. | Combinations comprising mek inhibitors for use in the treatment of cancer |
| EP4669319A1 (en) | 2023-02-23 | 2025-12-31 | Novartis AG | TEAD AND HER2 INHIBITOR COMBINATIONS FOR CANCER TREATMENT |
| WO2024176131A1 (en) | 2023-02-23 | 2024-08-29 | Novartis Ag | Tead- and kras g12d-inhibitor combinations for treating cancer |
| AU2024242687A1 (en) * | 2023-03-27 | 2025-10-09 | Vivace Therapeutics, Inc. | Synthesis of a hippo-yap pathway modulator and a polymorph thereof |
| WO2024216121A1 (en) * | 2023-04-14 | 2024-10-17 | Vivace Therapeutics, Inc. | Pharmaceutical formulations and dosing schedules of a hippo-yap pathway modulator |
| CN121219264A (zh) * | 2023-05-12 | 2025-12-26 | 正大天晴药业集团股份有限公司 | 含有芳香双并环的化合物 |
| KR20260029501A (ko) * | 2023-05-24 | 2026-03-04 | 베액티카 테라퓨틱스 아베 | Tead에 대한 결합제로서의 방향족 아미드 및 이의 접합체 |
| WO2025034563A1 (en) * | 2023-08-04 | 2025-02-13 | Vivace Therapeutics, Inc. | Compounds and methods for treating cancer |
| WO2025101655A1 (en) * | 2023-11-08 | 2025-05-15 | Vivace Therapeutics, Inc. | Compounds for modulating yap-tead/hippo pathway |
| WO2025122956A1 (en) * | 2023-12-08 | 2025-06-12 | Vivace Therapeutics, Inc. | Combination therapy |
| WO2025215527A2 (en) | 2024-04-10 | 2025-10-16 | Novartis Ag | Pharmaceutical combinations and uses thereof |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL135495A (en) | 1995-09-28 | 2002-12-01 | Hoechst Ag | Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid |
| AU6279598A (en) | 1997-02-18 | 1998-09-08 | Neurocrine Biosciences, Inc. | Biazacyclic CRF antagonists |
| PL341364A1 (en) | 1997-12-22 | 2001-04-09 | Upjohn Co | 4-hydroxyqinoline-3-carboxamides and hydrazides as antiviral agents |
| IT1303123B1 (it) | 1998-10-13 | 2000-10-30 | Rotta Research Lab | Derivati basici di benz(e)isoindol-1-oni e pirrolo(3,4-c)chinolin-1-oni ad attivita' 5ht3 antagonista, loro preparazione ed |
| WO2000075145A1 (en) | 1999-06-03 | 2000-12-14 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| AUPQ841300A0 (en) | 2000-06-27 | 2000-07-20 | Fujisawa Pharmaceutical Co., Ltd. | New aminoalcohol derivatives |
| US7067532B2 (en) | 2000-11-02 | 2006-06-27 | Astrazeneca | Substituted quinolines as antitumor agents |
| FR2827599A1 (fr) | 2001-07-20 | 2003-01-24 | Neuro3D | Composes derives de quinoleine et quinoxaline,preparation et utilisations |
| US7544699B2 (en) | 2003-08-08 | 2009-06-09 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions, and methods of use |
| WO2005082865A1 (ja) | 2004-02-27 | 2005-09-09 | Astellas Pharma Inc. | 縮合二環性ピリミジン誘導体 |
| WO2006080477A1 (en) * | 2005-01-25 | 2006-08-03 | Tanabe Seiyaku Co., Ltd. | Norvaline derivative and method for preparation thereof |
| BRPI0707302B8 (pt) | 2006-01-27 | 2021-05-25 | Fibrogen Inc | compostos de cianoisoquinolina que atuam no dano tecidual associado com isquemia, hipóxia e anemia, bem como composição farmacêutica que os compreende |
| WO2007097929A1 (en) | 2006-02-16 | 2007-08-30 | Fibrogen, Inc. | Compounds and methods for treatment of stroke |
| UY30183A1 (es) | 2006-03-02 | 2007-10-31 | Astrazeneca Ab | Derivados de quinolina |
| WO2008023157A1 (en) | 2006-08-21 | 2008-02-28 | Argenta Discovery Limited | Nitrogen containing heterocyclic compounds useful as m3-receptor modulators |
| AR065093A1 (es) | 2007-02-05 | 2009-05-13 | Merck Frosst Canada Ltd | Compuestos farmacéuticos inhibidores de la biosintesis de leucotrienos |
| CN101679357A (zh) | 2007-05-09 | 2010-03-24 | 辉瑞大药厂 | 取代的杂环衍生物及其组合物和作为抗菌剂的药物用途 |
| US20100254942A1 (en) | 2007-08-03 | 2010-10-07 | Biotron Limited | Hepatitis c antiviral compositions and methods |
| EA019869B1 (ru) | 2007-11-28 | 2014-06-30 | Дана Фарбер Кансер Инститьют, Инк. | Низкомолекулярные миристатные ингибиторы тирозинкиназы bcr-abl и способы их применения |
| WO2009075826A1 (en) | 2007-12-07 | 2009-06-18 | Fibrogen, Inc. | Methods for increasing white blood cells |
| KR20120006016A (ko) | 2009-04-06 | 2012-01-17 | 다이이찌 산쿄 가부시키가이샤 | 치환 페닐기를 갖는 고리형 화합물 |
| JP2012524800A (ja) | 2009-04-22 | 2012-10-18 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | モノアシルグリセロールリパーゼ阻害剤としてのアゼチジニルジアミド |
| EP2588455B1 (en) | 2010-07-02 | 2018-04-04 | Gilead Sciences, Inc. | 2-quinolinyl-acetic acid derivatives as hiv antiviral compounds |
| BR112013009828A2 (pt) | 2010-10-22 | 2016-07-26 | Janssen Pharmaceutica Nv | diamidas de amino-pirrolidina-azetidina como inibidores de monoacilglicerol lipase |
| CA2743391A1 (en) | 2011-05-27 | 2012-11-27 | Queen's University At Kingston | Compounds and methods for catalytic directed ortho substitution of aromatic amides and esters |
| IN2014CN03234A (enExample) | 2011-11-03 | 2015-07-03 | Merck Sharp & Dohme | |
| US9012443B2 (en) | 2011-12-07 | 2015-04-21 | Amgen Inc. | Bicyclic aryl and heteroaryl sodium channel inhibitors |
| EP2858635A1 (en) | 2012-06-11 | 2015-04-15 | The Regents of The University of California | Inhibitors of hippo-yap signaling pathway |
| EP3219706A1 (en) | 2012-07-16 | 2017-09-20 | Fibrogen, Inc. | Process for making isoquinoline compounds |
| CN105163727B (zh) | 2013-05-03 | 2018-08-17 | 豪夫迈·罗氏有限公司 | 刺激神经发生的异喹啉衍生物 |
| US20140336182A1 (en) | 2013-05-13 | 2014-11-13 | Amgen Inc. | Aurora Kinase Modulators and Method of Use |
| US9776995B2 (en) | 2013-06-12 | 2017-10-03 | Amgen Inc. | Bicyclic sulfonamide compounds as sodium channel inhibitors |
| US9452986B2 (en) * | 2014-02-06 | 2016-09-27 | Abbvie Inc. | 6-heteroaryloxy- or 6-aryloxy-quinoline-2-carboxamides and method of use |
| SG11201607973XA (en) | 2014-03-24 | 2016-11-29 | Guangdong Zhongsheng Pharmaceutical Co Ltd | Quinoline derivatives as smo inhibitors |
| CA2974078A1 (en) | 2015-01-20 | 2016-07-28 | Millennium Pharmaceuticals, Inc. | Quinazoline and quinoline compounds and uses thereof |
| WO2016153948A1 (en) * | 2015-03-20 | 2016-09-29 | Deuterx, Llc | Combination therapy using enantiopure, oxy-substituted, deuterium-enriched 5-(benzyl)-5-deutero-thiazolidine-2, 4-diones for treatment of medical disorders |
| WO2017058716A1 (en) * | 2015-09-28 | 2017-04-06 | Vivace Therapeutics, Inc. | Tricyclic compounds |
| EP3156404A1 (en) | 2015-10-15 | 2017-04-19 | Inventiva | New compounds inhibitors of the yap/taz-tead interaction and their use in the treatment of malignant mesothelioma |
| MA53943A (fr) * | 2015-11-20 | 2021-08-25 | Vitae Pharmaceuticals Llc | Modulateurs de ror-gamma |
| MX379513B (es) * | 2016-04-01 | 2025-03-11 | Signal Pharm Llc | Compuestos de aminopurina sustituida, composiciones de estos y métodos de tratamiento con estos. |
| WO2018028591A1 (zh) * | 2016-08-09 | 2018-02-15 | 殷建明 | 一种喹啉衍生物及其用途 |
| WO2018204532A1 (en) * | 2017-05-03 | 2018-11-08 | Vivace Therapeutics, Inc. | Non-fused tricyclic compounds |
| US11629220B2 (en) | 2017-08-21 | 2023-04-18 | Drexel Unversity | Renewable furan based amine curing agents for epoxy thermoset |
| CN117402114A (zh) * | 2018-01-26 | 2024-01-16 | 埃克塞里艾克西斯公司 | 用于治疗激酶依赖性病症的化合物 |
| EP3746135A4 (en) | 2018-01-30 | 2022-03-09 | Foghorn Therapeutics Inc. | METHODS AND COMPOUNDS FOR TREATMENT OF DISEASE |
| KR20210108367A (ko) | 2018-11-09 | 2021-09-02 | 비바체 테라퓨틱스, 인크. | 비시클릭 화합물 |
| MX2021012638A (es) | 2019-04-16 | 2022-01-04 | Vivace Therapeutics Inc | Compuestos biciclicos. |
| WO2022087008A1 (en) | 2020-10-21 | 2022-04-28 | Vivace Therapeutics, Inc. | Tertiary carboxamide compounds |
-
2020
- 2020-04-15 MX MX2021012638A patent/MX2021012638A/es unknown
- 2020-04-15 BR BR112021020629A patent/BR112021020629A2/pt unknown
- 2020-04-15 SG SG11202111404XA patent/SG11202111404XA/en unknown
- 2020-04-15 HU HUE20791635A patent/HUE070525T2/hu unknown
- 2020-04-15 IL IL287222A patent/IL287222B2/en unknown
- 2020-04-15 FI FIEP20791635.4T patent/FI3956033T3/fi active
- 2020-04-15 WO PCT/US2020/028363 patent/WO2020214734A1/en not_active Ceased
- 2020-04-15 CA CA3137025A patent/CA3137025A1/en active Pending
- 2020-04-15 TW TW109112690A patent/TWI849107B/zh active
- 2020-04-15 US US16/849,728 patent/US11420935B2/en active Active
- 2020-04-15 EP EP20791635.4A patent/EP3956033B1/en active Active
- 2020-04-15 DK DK20791635.4T patent/DK3956033T3/da active
- 2020-04-15 JP JP2021561601A patent/JP7653362B2/ja active Active
- 2020-04-15 KR KR1020217036838A patent/KR102909464B1/ko active Active
- 2020-04-15 CN CN202080044416.7A patent/CN114072207B/zh active Active
- 2020-04-15 ES ES20791635T patent/ES3014444T3/es active Active
- 2020-04-15 AU AU2020257207A patent/AU2020257207A1/en active Pending
- 2020-04-15 PL PL20791635.4T patent/PL3956033T3/pl unknown
-
2022
- 2022-05-24 US US17/752,649 patent/US12103902B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022529642A5 (enExample) | ||
| JP2022507020A5 (enExample) | ||
| JP2018503663A5 (enExample) | ||
| JP2017504576A5 (enExample) | ||
| JP5825535B2 (ja) | Ｈｅｃ１活性の調節因子およびそのための方法 | |
| AU2020322990B2 (en) | Class of triaromatic compounds targeting bifunctional phosphorylation site of STAT3 and applications thereof | |
| JP2009534457A5 (enExample) | ||
| JP2021523221A5 (enExample) | ||
| JP2020533288A5 (enExample) | ||
| JP2017502006A5 (enExample) | ||
| JP2017509682A5 (enExample) | ||
| JP2013528223A5 (enExample) | ||
| JP2017504595A5 (enExample) | ||
| RU2013104520A (ru) | Пирролопиримидиновые соединения и их применения | |
| RU2003114748A (ru) | Новые соединения, не являющиеся имидазолами | |
| JP2021521128A5 (enExample) | ||
| IL160851A (en) | Thiophene-and thiazolesulfonamide compounds, pharmaceutical compositions comprising them and use thereof in the manufacture of medicaments for treating susceptible neoplasms | |
| AU2021367554B2 (en) | Deuterated hpk1 kinase inhibitor, and preparation method therefor and use thereof | |
| CN109071561A (zh) | 用作泛素特异性蛋白酶抑制剂的噻吩并吡嗪甲酰胺 | |
| JP2020506970A5 (enExample) | ||
| JP2024504364A5 (enExample) | ||
| JP2025508323A5 (enExample) | ||
| JP2025508272A5 (enExample) | ||
| CN116113416A (zh) | 四环类衍生物、其制备方法和其医药上的用途 | |
| JP2014521609A5 (enExample) |